Understanding Factor X Deficiency – ICHCC
Iranian Comprehensive Hemophilia Care Center (ICHCC) shared a post on LinkedIn:
“Factor X deficiency (X as Roman numeral ten) is a bleeding disorder characterized by a lack in the production of factor X (FX), an enzyme protein that causes blood to clot in the coagulation cascade.
Produced in the liver, FX, when activated, cleaves prothrombin to generate thrombin in the intrinsic pathway of coagulation.
This process is vitamin K dependent and enhanced by activated factor V.
Symptoms may differ greatly, as apparently modifiers control to some degree the amount of FX that is produced.
Some affected individuals have few or no symptoms while others may experience life-threatening bleeding.
Typically this bleeding disorder manifests itself as a tendency to easy bruising, nose bleeding, heavy and prolonged menstruation and bleeding during pregnancy and childbirth, and excessive bleeding after dental or surgical interventions.
Newborns may bleed in the head, from the umbilicus, or excessively after circumcision.
Other bleeding can be encountered in muscles or joints, brain, gut, or urine.
While in congenital disease symptoms may be present at birth or show up later, in patients with acquired FX deficiency symptoms typically show up in later life.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan
-
Jun 9, 2026, 02:28Andreas Calatzis: Chasing Biologically Inactive Heparin?
-
Jun 9, 2026, 02:16Javier Lagos Servellon: Reflections on Completing the University of Bern’s Stroke Medicine Program
-
Jun 8, 2026, 17:50From Bleeding to Swelling – A Shared Therapeutic Revolution in Rare Diseases – RPTH Journal